您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Desmethylglycitein
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Desmethylglycitein
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Desmethylglycitein图片
CAS NO:17817-31-1
包装与价格:
包装价格(元)
1mg电议
5mg电议

产品介绍
Desmethylglycitein (4',6,7-Trihydroxyisoflavone),大豆苷元的代谢产物,来源于大豆 Glycine max,具有抗氧化性和抗癌活性。Desmethylglycitein 在体内直接结合 CDK1 和 CDK2,抑制 CDK1 和 CDK2 活性。Desmethylglycitein 是蛋白激酶 C (PKC)α 的直接抑制剂,抑制正常人皮肤成纤维细胞中的太阳紫外线 (sUV) 诱导的基质金属蛋白酶1 (MMP1)。Desmethylglycitein 以 ATP 竞争方式与细胞质中的 PI3K 结合,抑制 PI3K 和下游信号级联的活性,从而抑制 3T3-L1 前脂肪细胞中的脂肪形成。
Cas No.17817-31-1
别名4',6,7-三羟基异黄酮; 4',6,7-Trihydroxyisoflavone
Canonical SMILESO=C1C(C2=CC=C(O)C=C2)=COC3=CC(O)=C(O)C=C13
分子式C15H10O5
分子量270.24
溶解度DMSO: 125 mg/mL (462.55 mM)
储存条件Store at 2-8°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Desmethylglycitein (4',6,7-Trihydroxyisoflavone), a metabolite of daidzein, sourced from Glycine max with antioxidant, and anti-cancer activities.Desmethylglycitein binds directly to CDK1 and CDK2 in vivo, resulting in the suppresses CDK1 and CDK2 activity[1]. Desmethylglycitein is a direct inhibitor of protein kinase C (PKC)α, against solar UV (sUV)-induced matrix matrix metalloproteinase 1 (MMP1)[2]. Desmethylglycitein binds to PI3K in an ATP competitive manner in the cytosol, where it inhibits the activity of PI3K and downstream signaling cascades, leading to the suppression of adipogenesis in 3T3-L1 preadipocytes[3].

Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) suppesses anchorage-dependent growth of HCT-116 and DLD1 cells in a dose- and time-dependent manner without cytotoxicity [1].Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) suppresses CDK1 activity in a dose-dependent manner and inhibits CDK2 activity in HCT-116 cells[1].Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) induces cell cycle arrest at the S and G2/M phases, the percentage of cells in S phase is higher in the 100 μM 6,7,4′-THIF-treated group, and the same pattern is observed in G2/M phase (29.5% versus 19.1% ) [1]. Cell Viability Assay[1] Cell Line: HCT-116 cells

Desmethylglycitein (4',6,7-Trihydroxyisoflavone) (intraperitoneally injection; 5 or 25 mg/kg; once daily; 20 days) suppresses tumor development in mice and serves as an effective anticancer treatment with the potential to inhibit or delay the tumorigenicity of HCT-116 cells in an in vivo system[1]. Animal Model: Female athymic nude mice subcutaneously injected with HCT-116 cells[1]

[1]. Lee DE, et al. 6,7,4'-trihydroxyisoflavone inhibits HCT-116 human colon cancer cell proliferation by targeting CDK1 and CDK2. Carcinogenesis. 2011 Apr;32(4):629-35. [2]. Lim TG, et al. The daidzein metabolite, 6,7,4'-Trihydroxyisoflavone, is a novel inhibitor of PKCα in suppressing solar UV-induced matrix metalloproteinase 1. Int J Mol Sci. 2014 Nov 19;15(11):21419-32 [3]. Seo SG, et al. A metabolite of daidzein, 6,7,4'-trihydroxyisoflavone, suppresses adipogenesis in 3T3-L1 preadipocytes via ATP-competitive inhibition of PI3K.